<DOC>
	<DOCNO>NCT01974661</DOCNO>
	<brief_summary>The primary objective study answer question `` Is possible inject COMBIG-DC vaccine hepatic tumor without get unacceptable side effect '' ?</brief_summary>
	<brief_title>Phase I Safety Study Dendritic Cell Vaccine Treat Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>Patients diagnose hepatocellular carcinoma get COMBIG-DC vaccination three occasion 2-3 week 3-5 week vaccination 2 3 respectively . Adverse event register 6 month last vaccination , well change vital sign ( heart rate , blood pressure body temperature ) lab parameter . Immunologic response evaluate measure immunologic marker blood . The size tumor/tumors evaluate 3 6 month thereafter every three month tumor progression . For patient include approval Amendment 3 ( 2015-12-10 ) , COMBIG-DC give add standard treatment ; sorafenib Transarterial Chemoembolization ( TACE ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Be inform nature study provide write informed consent At least 18 year age . Diagnosis hepatocellular carcinoma accord EASL criterion pathology . Radiologically measurable liver tumor ( ) , i.e . least 20 mm long unidimensional diameter measure CT/MRI Not eligible curatively aim treatment TACE . Tumor stage B C accord BCLC . For patient include accord Amendment 3 : tumour stage A , B C accord BCLC 1. eligible sorafenib treatment ongoing sorafenib treatment 4 week ant time inclusion 2. eligible TACE receive 1 previous TACE treatment . Performance status &gt; ECOG 2 Liver function accord ChildPugh &gt; 7 point . Known major reaction/adverse event connection previously make vaccination ( e.g . asthma , anaphylaxia serious reaction ) . Known major reaction/adverse event connection previous transfusion blood product Active autoimmune disease require treatment systemic immunosuppressive agent , e.g . inflammatory bowel disease , multiple sclerosis , sarcoidosis , psoriasis , autoimmune hemolytic anemia , rheumatoid arthritis , SLE , vasculitis , Sj√∂gren 's syndrome , scleroderma , autoimmune hepatitis , rheumatological disease . Tested positive HIV Active disease ( HBV HCV ) require antiviral treatment Ongoing infection require treatment antibiotic antiviral medication Treatment immunosuppressive treatment like corticosteroid ( Immunosuppression ( within 28 day ) prior first injection COMBIGDC . Inhaled , intranasal local steroid accept ) , mTor inhibitor within 28 day first vaccination . Patients prior history malignancy HCC , within precede 3 year OR relaps complete response , except 5 year followup adequately treated situ carcinoma without recurrence nonmelanoma skin cancer . Inadequate laboratory parameter , i.e . : 1 . PProthrombincomplex ( PK ) &gt; 1.4 , 2 . Platelet count &lt; 50 75 x109/L 3 . Leukocyte count &lt; 3.0 x 109/L 4 . PAPT time outside normal limit Previous organ transplantation Women Childbearing Potential ( WOCBP ) refuse use adequate contraception ( oral injectable contraceptive , hormone release intrauterine device ) throughout study period . Pregnant lactate woman Life expectancy le 3 month . Concomitant antitumor treatment ( within 28 day ) prior first injection COMBIGDC , except sorafenib TACE patient include accord Amendment 3 . For patient include accord Amendment 3 : Previous systemic anticancer treatment . Investigational treatment ( within 28 day ) prior first injection COMBIGDC . Known blood dyscrasia ( bleed complication ) . Known malignancy CNS Any reason , opinion investigator , contraindicate patient participates study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>